Repository logo
 

Toxicological and Pharmacological Studies on Amide Derivatives of 5-Methoxymethyl-2'-Deoxycytidine

Date

1999

Journal Title

Journal ISSN

Volume Title

Publisher

ORCID

Type

Degree Level

Masters

Abstract

Toxicity has been a major problem in the development of drugs for the treatment of viral infections. Our hypothesis was that deoxycytidine analogs should have lower toxicity profile, because these pharmacophores would act selectively on virus infected cells. The antiviral activity of amide derivatives of 5-Methoxymethy1-2i-deoxycytidine (MMdCyd), namely, acetyl-MMdCyd, propanoyl-MMdCyd, butanoyl-MMdCyd and hexanoyl-MMdCyd against Herpes simplex virus type 1 (HSV-l), in A 549 cells and VERO cells was determined using the plaque reduction assay. The potency of MMdCyd and amide derivatives was higher in A549 cells as compared to VERO cells. Butanoyl-MMdCyd (But-MMdCyd) was the most potent compound in both cell lines. Concentrations of MMdCyd and But-MMdCyd required to inhibit 50% virus plaque formation (ED50) were 6.69 ± 0.70 and 0.87 ± 0.54 μM, respectively, in A549 cells. Butanoyl-MMdCyd was very effective in preventing cytopathogenic effects of HSV-1 and decreasing the production of infectious virus particles. The acute and delayed cytotoxicity of MMdCyd and But-MMdCyd was determined using CEM cells. Dideoxycytidine (ddC) was used as a positive control drug. At a concentration of 0.5 μM, ddC increased the doubling time of the cells, from the fourth day onward. MMdCyd and But-MMdCyd did not alter the doubling time of the cells up to 2000 μM (highest concentration tested).

Description

Keywords

Citation

Degree

Master of Science (M.Sc.)

Department

Graduate Studies and Research

Program

Toxicology

Committee

Part Of

item.page.relation.ispartofseries

DOI

item.page.identifier.pmid

item.page.identifier.pmcid